What is Depixus?
Depixus is at the forefront of molecular diagnostics, developing a suite of technologies designed to revolutionize the way genetic and epigenetic information is extracted from single DNA and RNA molecules. The company's proprietary methods promise speed, accuracy, and affordability, addressing critical needs in the life sciences sector. With validation of its core technologies in advanced stages and commercial development actively underway, Depixus is poised to make a substantial impact on genetic sequencing and analysis.
How much funding has Depixus raised?
Depixus has raised a total of $35.4M across 1 funding round:
Series A
$35.4M
Series A (2021): $35.4M with participation from Casdin Capital, Arix Bioscience, Bpifrance, and Lansdowne Partners
Key Investors in Depixus
Arix Bioscience
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. They provide capital and expertise to accelerate promising ideas into new treatments.
Bpifrance
Bpifrance finances companies at every stage of development with credit, guarantees, and equity, supporting innovation and international expansion. They offer a wide range of products and services for entrepreneurs.
Lansdowne Partners
Founded in 1998 and headquartered in London, UK, Lansdowne Partners is an investment management partnership focused on delivering superior long-term investment returns and exceptional client service.
What's next for Depixus?
The substantial enterprise-level funding and recent strategic investment signal Depixus's transition into a significant growth phase. This capital infusion is expected to accelerate commercialization efforts, expand market reach, and further refine its innovative single-molecule DNA and RNA extraction technologies. The company's trajectory suggests a focus on scaling operations and solidifying its position as a key player in the biotech and genetic sequencing industries, potentially paving the way for future expansion or strategic partnerships.
See full Depixus company page
